GlaxoSmithKline

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Established: 1929-01-01

Employees: 70.2K

Market Cap: $90B

Website: http://www.gsk.com

Introduction: GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Clinical Trials

Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD) -Study 2

Phase 3

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: FF
Drug: VI
Drug: Placebo
Drug: UMEC

First Posted Date: 2014-04-21

Last Posted Date: 2017-03-23

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 620

Registration Number: NCT02119286

Locations: 🇰🇷
GSK Investigational Site, Seoul, Korea, Republic of

A First Time in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK2798745 in Healthy Subjects and Stable Heart Failure Patients

Phase 2

Completed

Conditions: Oedema, Pulmonary

Interventions: Drug: GSK2798745 solution
Drug: GSK2798745 capsule
Drug: GSK2798745 suspension
Drug: Placebo capsule
Drug: Placebo solution
Drug: Placebo suspension

First Posted Date: 2014-04-21

Last Posted Date: 2018-09-27

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 61

Registration Number: NCT02119260

Locations: 🇬🇧
GSK Investigational Site, London, United Kingdom

Market Potential of Carbon Dioxide Nasal Spray

Phase 2

Completed

Conditions: Nasal Congestion

Interventions: Drug: Carbon Dioxide

First Posted Date: 2014-04-14

Last Posted Date: 2015-04-30

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 147

Registration Number: NCT02113449

Locations: 🇺🇸
Radiant Research - Cincinnati, Cincinnati, Ohio, United States
🇺🇸
Radiant Research - Pinellas Park, FL, Pinellas Park, Florida, United States
🇺🇸
TKL Research Inc, Paramus, New Jersey, United States

and more 1 locations

Efficacy and Safety of Fluticasone Propionate(FP)/ Salmeterol Xinafoate (SLM) Hydro Fluoro Alkane (HFA) Metered Dose Inhaler (MDI) in Pediatric Patients With Bronchial Asthma

Phase 4

Completed

Conditions: Asthma

Interventions: Drug: FP/ SLM HFA MDI 50/25 mcg
Drug: FP HFA MDI 50 mcg

First Posted Date: 2014-04-14

Last Posted Date: 2017-06-16

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 300

Registration Number: NCT02113436

Locations: 🇯🇵
GSK Investigational Site, Wakayama, Japan

Study to Assess Seroprevalence of Hepatitis A, Hepatitis B and Bordetella Pertussis in Mexico

Completed

Conditions: Viral Hepatitis Vaccines
Hepatitis A

Interventions: Other: Data collection

First Posted Date: 2014-04-14

Last Posted Date: 2019-06-27

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 1603

Registration Number: NCT02112890

Locations: 🇲🇽
GSK Investigational Site, Cuernavaca, Morelos, Mexico

Safety and Immunogenicity of GlaxoSmithKline Biologicals Meningococcal Group B Vaccine When Administered Concomitantly With GlaxoSmithKline Biologicals MenACWY Conjugate Vaccine to Healthy Infants

Phase 3

Completed

Conditions: Infections, Meningococcal

Interventions: Biological: Meningococcal group B Vaccine, rMenB+OMV NZ
Biological: Meningococcal ACWY Conjugate Vaccine, MenACWY

First Posted Date: 2014-04-08

Last Posted Date: 2018-08-22

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 750

Registration Number: NCT02106390

Locations: 🇲🇽
GSK Investigational Site, Morelia, Mexico

A Study to Evaluate the Cooling Sensation and Consumer Liking of a Skin Disinfectant Spray

Not Applicable

Completed

Conditions: Skin Care

Interventions: Other: Reference product
Other: Negative control
Other: Prototype disinfectant spray formulation

First Posted Date: 2014-04-08

Last Posted Date: 2015-02-11

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 50

Registration Number: NCT02106403

Locations: 🇨🇳
Guangzhou Landproof Testing Technology Co., LTD, Guangzhou, Guangdong, China

Efficacy and Safety of Mepolizumab as an Add-on Treatment in Chronic Obstructive Pulmonary Disease (COPD)

Phase 3

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Placebo
Drug: Mepolizumab

First Posted Date: 2014-04-07

Last Posted Date: 2018-08-16

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 674

Registration Number: NCT02105961

Locations: 🇬🇧
GSK Investigational Site, Stevenage, United Kingdom

Study to Evaluate Efficacy and Safety of Mepolizumab for Frequently Exacerbating Chronic Obstructive Pulmonary Disease (COPD) Patients

Phase 3

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Mepolizumab
Drug: Placebo

First Posted Date: 2014-04-07

Last Posted Date: 2018-08-31

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 837

Registration Number: NCT02105948

Locations: 🇸🇪
GSK Investigational Site, Stockholm, Sweden

Study Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Inhalation Powder (FF/VI) Compared With Vilanterol Inhalation Powder (VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Phase 3

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Vilanterol
Drug: Fluticasone Furoate/Vilanterol

First Posted Date: 2014-04-07

Last Posted Date: 2018-01-24

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 1621

Registration Number: NCT02105974

Locations: 🇺🇦
GSK Investigational Site, Vinnytsia, Ukraine

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy